Aims of the study
=================

To investigate the incidence and prognostic relevance of tumor micro-contamination in BM and/or G-CSF-mobilized peripheral blood progenitor cells collections of stage II-III breast cancer patients.

Patients and methods
====================

Patients were enrolled from September 1998 through May 1999 and underwent high-dose chemotherapy with autologous PBPC transplantation. We analysed a total of 71 patients for TC on PBPC apheresis (28 of them had previously frozen samples). 43/71 patients also had their BM evaluated on the day of the first PBPC collection after 5 days of G-CSF administration (BM-STIM) and immediately before HDCT (BM-PRECT). Cytokeratin (CK) expression was evaluated in all samples by either immunocytochemistry (ICC, sensitivity 1 × 10^-6^ cells, 9-16 × 10^-6^ cells for each sample) and reverse transcriptase nested PCR (RT-PCR, sensitivity 1 × 10^-7^cells). Amplified products were then annealed to a ^32^P-labelled internal sequence probe to confirm specificity. 41 patients were also evaluated by nested RT-PCR for Mammaglobin (*MAM*, sensitivity 1 × 10^-6^ cells) gene expression.

Results
=======

\(1\) PBPC frequency of CK+ was 11% by ICC and 66% by RT-PCR on 71 patients\' samples; (2) BMSTIM and BMPRECT frequency of CK+ was 7-14% by ICC and 60-65% by RT-PCR on 43 patients\' samples; (3) all CK ICC+ samples were *MAM RT-PCR+*; (4) 53% of patients with CK RT-PCR+ BM-STIM had their PBPC and BM-PRECT CK RT-PCR+; (5) after a median follow-up of 21 months on 28 patients with frozen samples, 25% of patients relapsed and 43% of them had contaminated PBPC; (6) 74% of CK ICC+ samples were CK RT-PCR+; (7) BMSTIM, PBPC and BMPRECT frequencies of *MAM+* were 15, 17 and 22% respectively by RT-PCR on 41 patients\' unfrozen samples; (8) PBPC frequency of *MAM+* was 20% by RT-PCR on 25 patients\' frozen samples.

Conclusion
==========

\(1\) *MAM* gene evaluation could add a lot of sensitivity and specificity to the overall results. (2) G-CSF administration for PBPC mobilization does not increase PBPC contamination. (3) A longer follow-up of these patients is needed to evaluate the prognostic relevance of different markers of tumor cell contamination in HDCT for breast cancer.
